Neoflam

Quick links to important sections

Neoflam

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Neoflam

This foundational section provides a concise overview of Neoflam's identity, composition, and general purpose, strictly avoiding specific usage instructions or clinical details.

Property Description
Active Ingredients Diclofenac Sodium and Naproxen
Form Oral Tablet/Capsule
Pharmacological Class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common Use Relief from pain, swelling, and inflammation
Origin Synthetic (Small molecule derivatives)

What Type of Medicine is Neoflam and How is it Classified?

Neoflam is classified as a synthetic Non-Steroidal Anti-Inflammatory Drug (NSAID), a pharmacological group of agents used widely to address pain and reduce inflammation. This specific product is formulated as a combination drug, which means it contains two distinct NSAID active substances, distinguishing it from standard single-agent formulations. Neoflam is typically classified as Prescription-Only (Rx), reflecting the need for medical guidance due to the potency of its combined agents.

What Active Ingredients Make Up Neoflam?

The active core of Neoflam is the pairing of Diclofenac Sodium (a phenylacetic acid derivative) and Naproxen (a propionic acid derivative). These two chemically non-identical NSAID compounds are synthesized and prepared together in a solid oral tablet or capsule. The deliberate combination of these two agents is intended to offer a comprehensive, broad-spectrum interference with inflammatory pathways via systemic absorption.

What is the General Purpose of Neoflam?

The general purpose of Neoflam is to provide comprehensive relief from pain, swelling, and inflammation by interfering with the chemical signals that trigger these symptoms. Both active ingredients function as non-selective inhibitors of the cyclooxygenase (COX) enzymes, thereby reducing the production of prostaglandins. This mechanism, which is clinically recognized for its effectiveness in managing inflammatory symptoms, is central to the drug’s core benefit: mitigating symptomatic discomfort.

Regulatory References

  1. NIH: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

What side effects are possible with Neoflam?

Possible Side Effects and Safety Information

Neoflam is a trade name for a Non-Steroidal Anti-Inflammatory Drug (NSAID) whose active ingredient is Ibuprofen. The safety profile is defined by the known risks associated with the NSAID class, particularly those affecting the gastrointestinal, cardiovascular, and nervous systems.

System-Organ Class Common Adverse Reactions Serious Adverse Reactions (Regulatory Warnings)
Gastrointestinal Upset stomach, heartburn, nausea, vomiting, abdominal pain Bleeding, ulceration, and perforation of the esophagus, stomach, or intestines, which can be fatal.
Cardiovascular Edema (fluid retention) Increased risk of serious thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. Risk may be increased in long-term use and in patients with heart disease.
Nervous System Headache, dizziness, fatigue, somnolence, insomnia, irritability Meningitis (aseptic), particularly in patients with pre-existing autoimmune conditions like Systemic Lupus Erythematosus (SLE).
Hypersensitivity/Skin Rash Anaphylactic reactions, exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and Toxic Epidermal Necrolysis (TEN).

Serious Safety Considerations

Official regulatory documents emphasize specific safety risks that require close monitoring during therapy:

  • Gastrointestinal Risk: This medication carries a warning for the risk of serious GI adverse events. This risk is greater for patients with a history of peptic ulcer disease, GI bleeding, or those using the medication for extended periods.
  • Cardiovascular Risk: NSAIDs may cause an increased risk of serious cardiovascular thrombotic events. This medication should be used with caution in patients with heart failure or hypertension.
  • Hepatic and Renal Toxicity: The use of this drug can be associated with toxicity to the liver and kidneys. Patients with impaired organ function or those on long-term therapy may require regular monitoring.
  • Pregnancy: The use of NSAIDs is generally restricted or contraindicated during the late stages of pregnancy due to the risk of premature closure of the ductus arteriosus in the fetus.

Overdose and Emergency Response

Overdose and When to Seek Help

This section details the officially documented clinical manifestations of Neoflam (Diclofenac Sodium and Naproxen combination) overdose and the mandatory regulatory requirements for seeking emergency assistance.

Documented Manifestations and Severe Outcomes

An over-ingestion of this medicine may affect the gastrointestinal (GI) tract and the central nervous system (CNS). Official regulatory documents list common manifestations as nausea, vomiting, epigastric pain, lethargy, drowsiness, and tinnitus.

More significant overdose scenarios carry the risk of severe or life-threatening outcomes. These documented complications include acute renal failure, severe gastrointestinal bleeding, convulsions, coma, and metabolic acidosis.

Required Emergency Actions

Regulatory authorities mandate that patients seek immediate medical attention or contact emergency services for any suspected or confirmed overdose. This action is required regardless of the presence or absence of initial symptoms, due to the potential for delayed serious effects. Immediate care is specifically necessary if severe manifestations such as disorientation, acute renal failure, or evidence of significant bleeding occur.

No specific antidote is known for Neoflam overdose. Clinical management is officially defined as symptomatic and supportive treatment, potentially involving measures like gastric lavage or activated charcoal for recent ingestions, and requiring hospital monitoring for observation.

Therapeutic Uses of Neoflam

What Neoflam treats: main uses and benefits

Neoflam is a medication belonging to the class of non-steroidal anti-inflammatory drugs (NSAIDs). It is primarily used to manage symptoms associated with inflammation and pain in various acute and chronic conditions.

Main Therapeutic Uses

The medication is most commonly utilized for its analgesic (pain-relieving) and anti-inflammatory properties. It is indicated for the following conditions:

  • Osteoarthritis: Management of pain and joint stiffness caused by the degeneration of cartilage.
  • Rheumatoid Arthritis: Reduction of joint swelling and pain associated with chronic autoimmune inflammation.
  • Ankylosing Spondylitis: Relief from inflammatory pain affecting the spine and large joints.
  • Acute Musculoskeletal Disorders: Treatment of pain resulting from sprains, strains, and other soft tissue injuries.
  • Post-Operative Pain: Management of inflammation and discomfort following surgical procedures.
  • Dysmenorrhea: Relief of pain associated with menstrual cramps.

Primary Benefits

Neoflam works by inhibiting the production of prostaglandins, which are chemicals in the body that signal pain and promote inflammation. By reducing the levels of these chemicals, the medication provides several clinical benefits:

Reduction of Inflammation

By targeting the underlying inflammatory process, the medication helps decrease localized swelling and redness. This is particularly beneficial for individuals with chronic joint diseases, as it can help maintain joint integrity over time.

Pain Management

Neoflam is effective in reducing different types of pain, ranging from dull aches associated with chronic conditions to sharp, acute pain resulting from injury. This helps improve the overall quality of life by allowing for more comfortable daily movement.

Improvement in Physical Function

For patients suffering from stiffness—especially morning stiffness in arthritic conditions—the reduction in inflammation can lead to improved mobility and a greater range of motion in the affected joints.

Regulatory References

  1. NIH MedlinePlus overview of Diclofenac

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Neoflam

The eligibility for Neoflam, a combination Non-Steroidal Anti-Inflammatory Drug (NSAID), is strictly defined by regulatory contraindications and population-specific restrictions.


Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults (18 years and older) who do not have documented contraindications or conditions requiring avoidance.
Populations for whom use is not recommended Patients with cardiovascular risk factors (e.g., hypertension, diabetes). Those with advanced renal disease or severe heart failure (unless benefits clearly outweigh risk). Pregnant women between 20 and 30 weeks gestation (limit use).
Populations for whom use is contraindicated Patients with known NSAID hypersensitivity or aspirin-sensitive asthma. Patients in the setting of Coronary Artery Bypass Graft (CABG) surgery. Patients with established congestive heart failure (NYHA Class II–IV), ischaemic heart disease, or cerebrovascular disease. Pregnant women at 30 weeks gestation and later.

Age-Related Eligibility Rules

Age Group Regulatory Status / Restriction
Children/Adolescents (Under 18) Safety and effectiveness have not been established for use.
Older Adults (Geriatric) At greater risk for serious gastrointestinal and renal adverse events, requiring caution.

Connection to the Overall Eligibility Profile

Regulatory documents define who can and cannot use the medicine by classifying certain pre-existing conditions and physiological states as absolute contraindications (e.g., CABG surgery, late pregnancy, and specific heart conditions). Eligibility is also constrained by the regulatory mandate that use is not established in the pediatric population and is limited in patients with compromised renal or hepatic function, requiring careful monitoring.

What should I know about interactions with other medicines?

The official regulatory profile for Neoflam, a combination Non-Steroidal Anti-Inflammatory Drug, is defined by significant pharmacokinetic and pharmacodynamic interactions and subsequent restrictions documented in government labeling.

Interaction-Related Restrictions and Classifications

Co-administration with other systemic NSAIDs is a formally contraindicated combination due to the severe, additive risk of gastrointestinal bleeding and ulceration. This medicine is also contraindicated in the setting of coronary artery bypass graft (CABG) surgery and for patients with a history of allergic-type reactions (asthma, urticaria) after taking aspirin or other NSAIDs. The use of alcohol is documented to exacerbate the inherent gastrointestinal bleeding risk.

Documented Exposure and Efficacy Interactions

Pharmacokinetic interactions are documented where this drug inhibits the renal clearance of substances with a narrow therapeutic index, such as Lithium, Digoxin, and Methotrexate. This interaction results in increased plasma concentrations of those co-administered medicines. Pharmacodynamic interactions are noted with Anticoagulants and SSRIs/SNRIs, which significantly increase the overall risk of serious bleeding. Furthermore, this medicine may diminish the antihypertensive effect of ACE inhibitors, ARBs, and Beta-Blockers, and reduce the natriuretic effect of diuretics. The combined use with ACE inhibitors or ARBs carries a heightened risk of renal function deterioration in the elderly or volume-depleted populations.

Mechanism of Action

Neoflam's action is defined by a dual-agent mechanism involving the non-steroidal active substances Diclofenac and Naproxen, designed to disrupt key processes in the eicosanoid and nociceptive pathways at multiple levels.

Core Enzyme Inhibition and Peripheral Blockade

The primary mechanism involves the non-selective inhibition of cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. This molecular intervention halts the conversion of arachidonic acid into prostaglandins and thromboxanes, which are the primary chemical mediators of vascular changes and nociceptor sensitization. This cascade modification results in a reduction of local vascular and cellular responses and the reduced chemical sensitization of peripheral nociceptors.

Central Nociception Modulation and Systemic Control

Beyond peripheral COX blockade, the drug engages mechanisms within the Central Nervous System ( CNS), such as the modulation of the NMDA receptor and acid-sensing ion channels (primarily mediated by Diclofenac). This action alters signaling dynamics in the neural pathways that transmit nociceptive signals. Concurrently, the inhibition of prostaglandin synthesis within the hypothalamus modulates the body's thermal set-point by inhibiting hypothalamic PGE2 synthesis.

Dual-Agent Pharmacodynamic Synergy

The combination allows the drug to influence core mechanisms underlying the pharmacodynamic profile via multiple complementary mechanisms. Naproxen contributes prolonged COX inhibition due to its long half-life, which complements Diclofenac's multi-modal, non-COX-mediated actions, influencing the dynamics within the targeted eicosanoid and nociceptive pathways.

Dosage and Administration Information

How to Use Neoflam: Official Administration Guidelines

The administration of Neoflam, a combination Non-Steroidal Anti-Inflammatory Drug (NSAID) containing Diclofenac and Naproxen, is governed by high-level principles established for its active components. These guidelines focus exclusively on the procedural and contextual rules for proper intake, dosage frequency, and constraints on the duration of treatment, and do not provide clinical advice.


Administration Scope Official Usage Instruction/Principle
Route of administration Administration is strictly via the oral route, with the medication being swallowed.
Dosing schedule Specific dosing tables for the combined agent are generally excluded from standard labels, as general principles advise against the concurrent use of two distinct oral NSAIDs. The primary instruction is to use the lowest effective dose.
Timing in relation to meals Ingestion with food or milk is commonly advised for many oral NSAID forms to help mitigate the potential for irritation to the gastrointestinal tract.
Age-group administration rules Explicit caution and the use of a lower starting dose are recommended for older adults. Use in patients with renal or hepatic impairment requires monitoring and dose minimization.

Procedural Structure and Administration Constraints

The official use protocol is defined by procedural and duration-based constraints. The frequency of intake is fixed by the formulation type—either once daily for extended-release forms or multiple times daily for immediate-release forms.

Official step sequence:

  • Swallow the tablet or capsule whole with water. Tablets designed with modified release (e.g., enteric-coated) must not be crushed, broken, or chewed.
  • Adhere to the predetermined frequency and avoid taking more than the prescribed amount.

Connection to the overall use protocol: The official use protocol for this medication is defined by a series of administrative constraints and high-level procedural rules. This structure dictates the proper physical intake method, the required temporal pattern of administration (frequency and duration), and the necessary adjustment in approach for certain sensitive populations. The instructions prioritize adherence to the principle of using the lowest quantity for the briefest time necessary.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Neoflam

The research evidence available for Neoflam, which combines Diclofenac and Naproxen, is largely derived from clinical studies and systematic reviews focused on the established use of the individual components and the wider Non-Steroidal Anti-Inflammatory Drug (NSAID) class. This overview summarizes the structure of the evidence and the main areas research has explored, according to regulatory and scientific literature.


Evidence for Chronic Inflammatory Joint Conditions

Clinical research has studied the use of these active ingredients in conditions characterized by fluctuating or episodic manifestations, particularly those involving chronic joint symptoms. The active components belong to the NSAID class, which has a substantial body of evidence applied in research contexts involving fluctuating or unstable symptoms. Research in this area has focused on outcomes related to physical discomfort and daily functioning or activity level.

Research Focused on Rheumatoid Arthritis

Clinical trials, including Randomized Controlled Trials (RCTs), have been conducted during periods of increased symptom activity in adults diagnosed with Rheumatoid Arthritis (RA). Researchers examined how patients reported changes in key outcomes like pain intensity, measures of joint swelling, and the duration of morning stiffness. Evidence from these trials contributes to understanding symptom patterns observed over the defined study periods, typically short-term follow-ups.

Research Focused on Osteoarthritis

The active components were evaluated in studies involving adults with Osteoarthritis (OA). These studies explored how patients reported perceived discomfort and standardized functional measures, which reflect daily functioning. Research often monitored the change in these functional scores over short and intermediate-term durations. What remains uncertain is the effect on the underlying joint deterioration or long-term disease progression, as research primarily explores outcomes related to physical discomfort and function over short-term intervals.


What Remains Uncertain in the Research Landscape

The overall evidence base contributes to the broader evidence landscape but highlights several key areas where research is ongoing. The primary limitation is that comparative evidence is lacking for the specific, fixed-dose combination of Diclofenac and Naproxen against other combination therapies; most conclusions rely on the established effects of the individual drugs. Additionally, long-term effects are not fully established, meaning the findings describe group patterns over defined time intervals but do not determine whether an individual will respond similarly or how they will fare over many years. Data for specific patient subgroups and long-term outcomes remain insufficient or evidence quality varies across studies.

Key Studies & References

  1. MedlinePlus Drug Information: Diclofenac
  2. MedlinePlus Drug Information: Naproxen
  3. NICE Guideline: Osteoarthritis: care and management

Frequently Asked Questions (FAQ)

Common questions about Neoflam (FAQ)


Q: Is Neoflam the same as other common anti-inflammatory medicines?

Regulatory classification states that Neoflam is a Non-Steroidal Anti-Inflammatory Drug (NSAID). Its composition is unique because it is formulated as a combination medicine containing two distinct active substances: Diclofenac and Naproxen. The official composition of the two active substances distinguishes it from single-agent NSAIDs.


Q: Is it possible to take Neoflam on an empty stomach?

Official labeling generally advises taking oral NSAIDs with food or milk to help reduce the potential for irritation to the lining of the stomach and intestines. Taking it on an empty stomach may increase the potential for gastrointestinal irritation.


Q: Does Neoflam cause drowsiness or affect alertness?

Official regulatory documents list adverse reactions related to the nervous system, which can include dizziness and somnolence (sleepiness). Regulatory documents list these effects, and they may affect a person's level of alertness.


Q: Does taking Neoflam with certain supplements cause issues?

Regulatory documents primarily focus on interactions with prescription medicines, such as anticoagulants and diuretics. While specific supplements are generally not listed, the documented risk of serious bleeding is increased with co-administration of substances that may affect blood clotting or stomach integrity.


Q: What is the maximum number of days Neoflam is usually prescribed for?

Official guidance mandates using the lowest effective dose for the shortest duration necessary to minimize potential risks. This principle is applied to the duration of treatment, especially for acute conditions.


Q: Do studies suggest Neoflam has been researched in children?

According to official regulatory documents, the safety and effectiveness of this combination product have not been established for use in the pediatric population (those under 18 years of age).


Q: What is the key difference between immediate-release and extended-release Neoflam?

The difference relates to the design of the pill and how the drug is absorbed by the body. Immediate-Release forms allow for rapid absorption, while Extended-Release forms are designed to release the active substance slowly over time, allowing for a sustained effect.


Q: Can Neoflam be taken long-term for chronic conditions?

Official warnings emphasize that use for chronic conditions must balance symptomatic relief with the recognized risk that serious adverse events, such as heart attack, stroke, or GI bleeding, may increase with the duration of use.


Q: How quickly does Neoflam start working after you take it?

Official information describes the time it takes to reach peak concentration in the blood, which for the active components is typically within one to four hours after administration. This generally corresponds to the timeframe when the drug begins to exert its effects.


Q: How long does the effect of Neoflam usually last?

The duration of the effect is related to the half-life of its components. One active component has a short half-life (1–2 hours), while the other has a longer half-life (12–17 hours), reflecting the different pharmacodynamic contributions of the two active substances.


Q: Can Neoflam be taken for headaches or migraines?

Regulatory documents state that the drug class is indicated for the relief of pain and inflammation. The specific official approval for the medicine will state the full range of conditions for which it is formally indicated, such as specific inflammatory joint conditions and acute pain.


Q: What are the signs that Neoflam might be interacting with another drug?

Official documentation outlines potential consequences of serious interactions. These may include signs of increased bleeding risk (such as unusual bruising or blood in the stool) or signs of kidney function deterioration (such as reduced urination or swelling in the limbs).


Q: Is Neoflam available without a prescription in some places?

Neoflam is generally classified as a Prescription-Only (Rx) medicine due to the combined potency and safety profile of its active ingredients. However, the individual components are available in lower-dose, over-the-counter (OTC) products in some regions.


Q: What is the difference between Neoflam and Tylenol (acetaminophen)?

Neoflam is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) that acts to reduce both pain and inflammation. Acetaminophen (Tylenol) belongs to a different class; it primarily relieves pain and fever, and generally does not have significant anti-inflammatory properties.


Q: Is there a generic version of Neoflam available?

The availability of a generic version is determined by the regulatory status and patent expiration in each country. Regulatory records track the listing and approval status for generic versions of the combined active ingredients.


Q: Do official documents mention any connection between Neoflam and dizziness?

Yes, official regulatory documents list dizziness among the reported adverse reactions to the active ingredients. This is noted along with other central nervous system effects, such as headache and somnolence (sleepiness).


Q: What is meant by the 'half-life' of Neoflam?

The term half-life refers to the time required for the concentration of a drug's active substance in the body's plasma (blood) to be reduced by half. Since Neoflam has two active components, each has its own distinct half-life that contributes to the drug's overall profile.


Q: Are there different forms of Neoflam (e.g., tablet, gel, injection)?

Neoflam is typically supplied as an oral tablet or capsule. The individual active components, Diclofenac and Naproxen, are available in various formulations depending on the country and local regulations, which can include topical gels, solutions, or injections.


Q: Is Neoflam a commonly used treatment for arthritis?

Yes, the active components are specifically indicated in official documentation for the relief of the signs and symptoms of inflammatory joint conditions such as rheumatoid arthritis and osteoarthritis.


Q: Does Neoflam have any known impact on fertility?

Official documentation for the NSAID class advises that these agents may impair female fertility and are not recommended for women who are actively trying to conceive. This effect is generally described as reversible upon stopping the drug.


Q: Is it possible for Neoflam to cause changes in mood or sleep?

Official documents list effects on the nervous system and psychiatric disorders as potential adverse reactions, which can include insomnia (trouble sleeping) and, less commonly, irritability.


Q: What is the typical timeframe for seeing the full anti-inflammatory effect?

Regulatory information suggests that the full therapeutic benefit for inflammatory conditions may require continuous treatment, sometimes taking up to one to two weeks.


Q: Is there a known cumulative effect if Neoflam is taken daily?

Official safety warnings describe the risk of serious adverse events, particularly cardiovascular events (like heart attack and stroke) and gastrointestinal bleeding, as increasing with the duration of use.


Q: Do drug labels mention if Neoflam can cause sensitivity to the sun?

Official regulatory information for NSAIDs often lists photosensitivity reactions (increased skin sensitivity to sunlight) as a potential adverse reaction.


Q: Why is a prescription often needed for Neoflam?

The medicine is classified as Prescription-Only (Rx) due to the recognized risk profile associated with the combination of two active NSAIDs. This classification reflects the need for professional medical oversight to manage the risk of serious cardiovascular and gastrointestinal adverse events.

How should Neoflam be stored and disposed of?

Official Storage and Disposal Statements

Scope Item Official Regulatory Requirement
Storage Temperature Store at controlled room temperature (20 C to 25 C).
Environmental Protection Protect the medicine from moisture and heat. Do not freeze the product.
Container Rules Keep the medicine in the original container and maintain a tightly closed lid.
Child Safety Keep out of the reach of children.
Disposal Consult a healthcare professional regarding the disposal of unused or expired product; do not flush down the toilet.

These requirements, defined in official regulatory documents, ensure the stability and safety of the product. The storage temperature range prevents degradation, while protection from moisture and freezing maintains chemical integrity. Proper disposal methods are required to minimize risk and protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Neoflam found in:

A-Z Index: